Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. reports asset-sale, governance, clinical and regulatory, and corporate-status developments tied to its history as a clinical-stage biopharmaceutical company developing immunotherapeutics for cancer and serious infectious diseases. Its disclosed programs included arenavirus-platform cancer vaccine assets such as HB-200 (eseba-vec) and HB-700, as well as HB-400 for hepatitis B virus and HB-500 for HIV.
Company updates have covered completed sales of oncology, HBV, and HIV program assets, collaboration-related activity, board and stockholder matters, operating and financial results, and the voluntary delisting and deregistration process for HOOKIPA common stock.
HOOKIPA Pharma announced that the first data from their Phase 1 study on HB-201/HB-202, an arenaviral therapeutic for HPV16+ cancers, will be presented at the ASCO Annual Meeting from June 4-8, 2021. This includes safety, tolerability, and preliminary anti-tumor activity from 40 patients. The presentation highlights the potential of HOOKIPA's novel immunotherapeutics to enhance cancer treatment. Following the presentation, an investor event will provide insights into the trial's findings and HOOKIPA's future plans.
HOOKIPA Pharma reported encouraging preliminary Phase 1 data for its oncology candidates, HB-201 and HB-202, showing a robust antigen-specific CD8+ T cell response following one dose. The results align with prior pre-clinical studies, demonstrating an increase of up to 8% in antigen-specific circulating CD8+ T cells in patients with HPV16+ cancers. Financially, HOOKIPA posted revenues of $5.3 million for Q1 2021, up from $3.7 million in Q1 2020. However, net loss widened to $17.2 million, reflecting increased R&D expenses. The company is set to present further data at ASCO and other upcoming conferences.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is set to report its first quarter 2021 financial results on May 12, 2021. The company specializes in developing immunotherapeutics utilizing its proprietary arenavirus platform, which targets immune system activation. HOOKIPA's products include HB-201 and HB-202 for HPV-related cancers and HB-101, a vaccine for Cytomegalovirus in kidney transplant patients, both in clinical trials. HOOKIPA has also partnered with Gilead Sciences to explore HIV and Hepatitis B treatments.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced its participation in several upcoming virtual investor conferences. Key events include the 7th Annual Truist Securities Life Sciences Summit on May 4, the Bank of America Health Care Conference on May 13, the Morgan Stanley Asia Healthcare Conference on May 13-14, and the RBC Capital Markets Global Healthcare Conference on May 18. Live webcasts will be accessible on HOOKIPA's website, with replays available for 30 days. HOOKIPA is focused on developing innovative immunotherapeutics using its proprietary arenavirus platform.
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a biopharmaceutical company focused on immunotherapeutics, announced its participation in the virtual Kempen Life Science Conference on April 21, 2021. The management team will host one-on-one meetings during the event. HOOKIPA is advancing a pipeline targeting virally mediated cancer antigens and infectious diseases, including its lead oncology candidates, HB-201 and HB-202, in Phase 1/2 trials. The company also collaborates with Gilead Sciences to explore functional cures for HIV and Hepatitis B infections, showcasing its innovative approach to immunotherapy.
HOOKIPA Pharma announced positive preliminary Phase 1 data for oncology candidates HB-201 and HB-202 targeting HPV16+ cancers. Key highlights include up to an 8% increase in circulating CD8+ T cells and significant immune activation, notably an increase in interferon-gamma. Presented at the AACR Annual Meeting, these results reinforce previous findings of anti-tumor activity. The ongoing Phase 1/2 study (NCT04180215) is exploring various dosing strategies with potential for major advancements in treatment options for metastatic HPV16+ cancers.
HOOKIPA Pharma reported a strong financial position with a cash balance of $143 million at year-end 2020, bolstered by a $80.9 million financing and collaboration revenue of $19.6 million from Gilead. The oncology candidate HB-201 demonstrated promising anti-tumor activity in HPV16+ cancers, while HB-101 showed effectiveness in reducing CMV viremia in kidney transplant patients. The company aims for additional clinical data in 2021, showcasing the potential of its proprietary arenavirus platform for immunotherapeutics.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is set to release its fourth quarter and full year 2020 financial results on March 18, 2021, before market opens. A live conference call will follow at 8:30 am EDT to discuss the results and provide a corporate update. HOOKIPA is focused on developing immunotherapeutics using its proprietary arenavirus platform, with candidates HB-201 and HB-202 in a Phase 1/2 trial for HPV 16-positive cancers, and HB-101 in a Phase 2 trial for CMV vaccination in kidney transplant patients. The company has also partnered with Gilead Sciences for HIV and hepatitis B research.
HOOKIPA Pharma (NASDAQ: HOOK) announced significant pre-clinical data showcasing their innovative 2-vector system for cancer treatment in the journal Cell Reports Medicine. This method demonstrated tumor-specific responses exceeding 50% of circulating CD8 T cells, resulting in tumor cures and long-term immunity. The alternating administration of arenaviral vectors showed no vector-neutralizing antibodies, indicating the possibility of repeated treatments. HOOKIPA is evaluating this technology in an ongoing Phase 1/2 clinical trial for HPV16+ cancers, with promising interim results expected by mid-2021.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The presentation will be available starting March 09, 2021, at 7:00 AM ET via a webcast on HOOKIPA's official website. The company is focused on developing immunotherapeutics using its proprietary arenavirus platform, targeting cancers and infectious diseases. Notably, their product candidates, HB-201 and HB-202, are in Phase 1/2 trials for HPV-positive cancers, while HB-101 is in a Phase 2 trial for kidney transplant patients.